AbbVie: EC expands VENCLYXTO label in first-line CLL
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase…
#Europe #EU #ABBV #AbbVie #chroniclymphocyticleukemia #CLLtreatment #European #EuropeanCommission #labelexpansion #VENCLYXTO #venetoclax
https://www.europesays.com/europe/55608/